検索結果

Search Results for " c-Abl "

阻害剤

リコンビナントタンパク質

カタログ番号	製品名	別名	ターゲット
T39827	c-ABL-IN-1
	C-ABL-IN-1 is a new and specific inhibitor of the c-Abl protein, which effectively prevents the progression of neurodegeneration observed in Parkinson's disease.
T21785	AG957		Bcr-Abl
	Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors[1].		Bcr-Abl
T61546	c-ABL-IN-3
	c-ABL-IN-3, a highly effective c-Abl inhibitor, exhibits promising potential for studying neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), as well as cancer [1]. The ac...
T62065	c-ABL-IN-4
	c-ABL-IN-4 is a potent inhibitor of c-Abl.
T79716	c-ABL-IN-5		Bcr-Abl
	C-ABL-IN-5, a selective c-Abl inhibitor, exhibits neuroprotective properties and has favorable characteristics including blood-brain barrier permeability, metabolic stability, and pharmacokinetic profiles. When labeled w...		Bcr-Abl
T61128	c-ABL-IN-2
	C-ABL-IN-2 is a highly effective inhibitor of the c-Abl protein, which plays a significant role in the development of several diseases, including cancer. This compound exhibits promise for investigating neurodegenerative...
T7861	Flumatinib mesylate	HHGV678 mesylate	Bcr-Abl , PDGFR , c-Kit
	Flumatinib mesylate (HHGV678 mesylate) is a selective inhibitor of c-Abl, PDGFRβ and c-Kit, effectively overcomes drug resistance of certain KIT mutants.		Bcr-Abl , PDGFR , c-Kit
T4320	Flumatinib	HHGV678	Bcr-Abl , PDGFR , c-Kit
	Flumatinib (HHGV678) is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.		Bcr-Abl , PDGFR , c-Kit
T4191	Multi-kinase inhibitor 1	Multi-kinase inhibitor I	Others , Bcr-Abl , PDGFR , c-Kit
	Multi-kinase inhibitor 1 (Multi-kinase inhibitor I) is a Multi-kinase inhibitor.		Others , Bcr-Abl , PDGFR , c-Kit
T11641	N-Desmethyl imatinib	Imatinib metabolite N-Desmethyl imatinib,Norimatinib	Bcr-Abl , PDGFR , c-Kit , Drug Metabolite
	N-Desmethyl imatinib (Imatinib metabolite N-Desmethyl imatinib) is a metabolite of Imatinib, which is a multi-target inhibitor of c-Kit, v-Abl, and PDGFR.		Bcr-Abl , PDGFR , c-Kit , Drug Metabolite
T6230	Imatinib	STI571,CGP057148B,ST-1571	SARS-CoV , Bcr-Abl , PDGFR , c-Kit , Autophagy
	Imatinib (STI571) is a multi-targeted receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of BCR/ABL, v-Abl, PDGFR, and c-kit with oral activity. Imatinib has antitumor activity for the tre...		SARS-CoV , Bcr-Abl , PDGFR , c-Kit , Autophagy
T4053	AST 487	NVP-AST 487	VEGFR , FLT , c-RET , Bcr-Abl , c-Kit
	AST 487 (NVP-AST 487) is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. It also can inhibit Flt-3.		VEGFR , FLT , c-RET , Bcr-Abl , c-Kit
T1621	Imatinib Mesylate	ST-1571 Mesylate,STI-571,CGP-57148B	Bcr-Abl , PDGFR , c-Kit , Autophagy
	Imatinib Mesylate (STI-571) is a tyrosine kinase receptor inhibitor with antineoplastic activity (IC50s: 0.6 μM, 0.1 μM and 0.1 μM for v-Abl, c-Kit and PDGFR, respectively).		Bcr-Abl , PDGFR , c-Kit , Autophagy
T4618	BGG463	K 0859	Bcr-Abl , CDK
	BGG463 (K 0859) can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with a 50% inhibitory concentration (IC50) of 0.25 μM, 0.09 μM and 0.590 μM, respectively.		Bcr-Abl , CDK
T6348	NVP-BHG712		Raf , Bcr-Abl , Src , Ephrin Receptor
	NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM, respecti...		Raf , Bcr-Abl , Src , Ephrin Receptor
T3935	1-Naphthyl PP1	1-NA-PP 1	Src
	1-Naphthyl PP1 (1-NA-PP 1) is a selective src inhibitor(v-Src and c-Fyn, c-Abl, CDK2 and CAMK II with IC50s of 1.0, 0.6, 0.6, 18 and 22 μM, respectively)		Src
T15164	DPH		Bcr-Abl
	DPH is a potent cell permeable activator of c-Abl. It shows potent enzymatic and cellular activity in stimulating c-Abl activation.		Bcr-Abl
T22552L	AD57		Bcr-Abl , Src
	AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.		Bcr-Abl , Src
T6311	Bafetinib	NS-187,INNO-406	Bcr-Abl , Src , Autophagy
	Bafetinib (INNO-406) (INNO-406) is an effective and specific dual Bcr-Abl/Lyn inhibitor (IC50: 5.8/19 nM), and no inhibition of the phosphorylation of the T315I mutant and less effective to c-Kit and PDGFR.		Bcr-Abl , Src , Autophagy
T7371	1-Naphthyl PP1 hydrochloride	1-NA-PP 1 hydrochloride	Src
	1-Naphthyl PP1 hydrochloride (1-NA-PP 1 hydrochloride) is a selective inhibitor of src family kinases v-Src		Src
T2293	SGX-523		Raf , p38 MAPK , c-Met/HGFR , Bcr-Abl
	SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.		Raf , p38 MAPK , c-Met/HGFR , Bcr-Abl
T2640	Rebastinib	DCC2036,DCC 2036,DCC-2036	Apoptosis , FLT , Bcr-Abl , Src
	DCC-2036 (Rebastinib (DCC-2036)) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC, HCK, FGR, FLT3, KDR, and Tie-2, and low activity to c-Kit. Re...		Apoptosis , FLT , Bcr-Abl , Src
T4014	CP-724714	CP724714,CP 724714	Apoptosis , EGFR
	CP-724714 (CP724714) is an effective and selective HER2/ErbB2 inhibitor (IC50: 10 nM), >640-fold selectivity against EGFR, Abl, InsR, PDGFR, IRG-1R, Src, VEGFR2, c-Met etc.		Apoptosis , EGFR
T6079	NVP-ADW742	ADW742,ADW,GSK 552602A	Apoptosis , IGF-1R
	NVP-ADW742 (ADW) is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.		Apoptosis , IGF-1R
T6277	Doramapimod	BIRB 796	Raf , p38 MAPK , Autophagy
	Doramapimod (BIRB 796) is a highly potent inhibitor of p38 MAPK (Kd: 0.1 nM), but weakly inhibits c-RAF, Fyn, Lck, ERK-1, SYK, IKK2, and ZAP-70.		Raf , p38 MAPK , Autophagy
T2624	OSI-930	OSI 930	Apoptosis , c-Fms , Raf , VEGFR , FLT , CSF-1R , Src , c-Kit
	OSI-930, an orally active inhibitor of c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2), targets cancer cell proliferation and blood vessel growth (angiogenesis) in tumors.
T67847	Imatinib impurities3		Bcr-Abl , PDGFR , c-Kit
	Imatinib impurities3 is a protein kinases inhibitor with IC50 values of 6.95uM, 0.245uM, 0.139uM for ABL1 wt, KIT wt, PDGFRR wt, respectively.		Bcr-Abl , PDGFR , c-Kit
T10801	CHMFL-ABL/KIT-155	CHMFL-ABL-KIT-155	c-Kit
	CHMFL-ABL/KIT-155 is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s: 46 nM/75 nM). It arrests cell cycle progression and induces apoptosis.		c-Kit
T27212	DSA-7	DSA7
	DSA7 is a potent inhibitor of c-Src and Abl.
T22303	Dasatinib hydrochloride	BMS-354825 HCl	Bcr-Abl , Src , c-Kit
	Dasatinib hydrochloride (BMS-354825 HCl) (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bc...		Bcr-Abl , Src , c-Kit
T1448L	Dasatinib monohydrate	BMS-354825 Monohydrate	Apoptosis , Bcr-Abl , Src , c-Kit , Ephrin Receptor , Autophagy
	Dasatinib monohydrate (BMS-354825 Monohydrate) is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib monohydrate binds to and inhibits the growth-promoting activit...
T83711	Abl Substrate Peptide TFA
	Abl substrate peptide, a peptide substrate specifically phosphorylated by the tyrosine kinase Abl rather than c-Src kinase at 20 µM, serves to quantify Abl kinase activity in vitro. This selective phosphorylation undersc...
T11640	Imatinib-d8	CGP-57148B D8,STI571 D8	Others
	Imatinib D8 is a deuterium-labeled Imatinib. Imatinib is an orally bioavailable tyrosine kinases inhibitor that inhibits BCR/ABL, PDGFR, v-Abl, and c-kit kinase activity.		Others
T11639	Imatinib D4	CGP-57148B D4,STI571 D4	Others
	Imatinib D4 is a deuterium-labeled Imatinib. Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, PDGFR, v-Abl, and c-kit kinase activity.		Others
T23128	PD180970	PD 180970	Bcr-Abl , Src , c-Kit
	PD180970 is an inhibitor of Bcr-Abl with IC50s of 5 nM, 0.8 nM and 50 nM for the autophosphorylation of p210Bcr-Abl, Src and Kit. PD180970 can be used in studies about chronic myelogenous leukemia.		Bcr-Abl , Src , c-Kit
T2116	AEE788	NVP-AEE 788	Apoptosis , EGFR , c-Fms , FLT , Bcr-Abl
	AEE788 (NVP-AEE 788) has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Brain and Central Nervous System Tumors.		Apoptosis , EGFR , c-Fms , FLT , Bcr-Abl
T40504	N-Desmethyl imatinib mesylate	ImatinibmetaboliteN-Desmethylimatinibmesylate,N-Desmethyl imatinib mesylate,Norimatinib mesylate
	Norimatinib mesylate, also known as N-Desmethyl imatinib mesylate, is a metabolite derived from Imatinib, which acts as a potent multi-target inhibitor of v-Abl, c-Kit, and PDGFR.
T22859	Imatinib hydrochloride		Others
	Imatinib is a multi-target inhibitor of v-Abl, c-Kit, and PDGFR (IC50: 0.6 μM, 0.1 μM, and 0.1 μM, respectively). Imatinib is used to treat chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs), and...		Others
T3641	NVP-BAW2881	BAW2881	Raf , VEGFR , Bcr-Abl
	NVP-BAW2881 (BAW2881) is a potent and selective VEGFR inhibitor (vascular endothelial growth factor receptor tyrosine kinase inhibitor) with activity to inhibit chronic and acute skin inflammation.		Raf , VEGFR , Bcr-Abl
T68581	AP23464
	AP23464 is a potent adenosine 5'-triphosphate (ATP)-based inhibitor of Src and Abl kinases, displays antiproliferative activity against a human CML cell line and Bcr-Abl-transduced Ba/F3 cells (IC(50) = 14 nM. AP23464 ab...
T73973	Imatinib Impurity E
	Imatinib Impurity E is a specific impurity found in Imatinib, an orally available inhibitor of multiple tyrosine kinases, including BCR/ABL, v-Abl, PDGFR, and c-kit. Imatinib (STI571) operates by semi-competitively inhib...
T1448	Dasatinib	BMS-354825	Apoptosis , Bcr-Abl , Src , c-Kit , Autophagy
	Dasatinib (BMS-354825) is a tyrosine kinase inhibitor that inhibits Src and Bcr-Abl (Ki=16/30 pM) and is orally active and ATP-competitive. Dasatinib has antitumor activity and is used in the treatment of leukemia and ly...		Apoptosis , Bcr-Abl , Src , c-Kit , Autophagy
T2609	Masitinib	AB1010	Apoptosis , FAK , c-Fms , FGFR , Bcr-Abl , PDGFR , Src , c-Kit , Hck
	Masitinib (AB1010) is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet...
T2070	Agerafenib	RXDX-105,CEP 32496,CEP-32496,CEP32496	Raf , c-RET , Bcr-Abl , PDGFR , Src , c-Kit
	Agerafenib (CEP32496) is a highly potent inhibitor of BRAF.		Raf , c-RET , Bcr-Abl , PDGFR , Src , c-Kit
T2372	Ponatinib	AP24534	VEGFR , FGFR , Bcr-Abl , PDGFR , Src , c-Kit , Autophagy
	Ponatinib (AP24534) is an orally available, multitargeted kinase inhibitor (IC50s: 0.37/1.1/1.5/2.2/5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively).		VEGFR , FGFR , Bcr-Abl , PDGFR , Src , c-Kit , Autophagy
T21295	BIX02189	BIX 02189	ERK , MEK
	BIX02189 is a potent and selective inhibitor of MEK5 and ERK5(IC50 : 1.5 nM and 59 nM).		ERK , MEK
T1744	BIX02188		Apoptosis , MEK
	BIX02188 is a selective and potent MEK5 inhibitor that inhibits MEK5-induced apoptosis in cells expressing the oncogenic mutant FLT3-ITD.		Apoptosis , MEK
T14928	Agerafenib hydrochloride	RXDX-105 hydrochloride,CEP-32496 (hydrochloride)	c-RET , c-Kit
	Agerafenib hydrochloride is a highly potent inhibitor of BRAFV600E (Kd: 14 nM).		c-RET , c-Kit

Compounds

Synonym: HHGV678 mesylate

Target: Bcr-Abl, PDGFR, c-Kit

Flumatinib

T4320

Synonym: HHGV678

Target: Bcr-Abl, PDGFR, c-Kit

Multi-kinase inhibitor 1

T4191

Synonym: Multi-kinase inhibitor I

Target: Others, Bcr-Abl, PDGFR, c-Kit

N-Desmethyl imatinib

T11641

Synonym: Imatinib metabolite N-Desmethyl imatinib,Norimatinib

Target: Bcr-Abl, PDGFR, c-Kit, Drug Metabolite

Imatinib

T6230

Synonym: STI571,CGP057148B,ST-1571

Target: SARS-CoV, Bcr-Abl, PDGFR, c-Kit, Autophagy

AST 487

T4053

Synonym: NVP-AST 487

Target: VEGFR, FLT, c-RET, Bcr-Abl, c-Kit

Imatinib Mesylate

T1621

Synonym: ST-1571 Mesylate,STI-571,CGP-57148B

Target: Bcr-Abl, PDGFR, c-Kit, Autophagy

BGG463

T4618

Synonym: K 0859

Target: Bcr-Abl, CDK

NVP-BHG712

T6348

Synonym:

Target: Raf, Bcr-Abl, Src, Ephrin Receptor

Target: Bcr-Abl, Src

Bafetinib

T6311

Synonym: NS-187,INNO-406

Target: Bcr-Abl, Src, Autophagy

1-Naphthyl PP1 hydrochloride

T7371

Synonym: 1-NA-PP 1 hydrochloride

Target: Raf, p38 MAPK, c-Met/HGFR, Bcr-Abl

Rebastinib

T2640

Synonym: DCC2036,DCC 2036,DCC-2036

Target: Apoptosis, FLT, Bcr-Abl, Src

CP-724714

T4014

Synonym: CP724714,CP 724714

Target: Apoptosis, EGFR

NVP-ADW742

T6079

Synonym: ADW742,ADW,GSK 552602A

Target: Apoptosis, IGF-1R

Doramapimod

T6277

Synonym: BIRB 796

Target: Raf, p38 MAPK, Autophagy

OSI-930

T2624

Synonym: OSI 930

Target: Apoptosis, c-Fms, Raf, VEGFR, FLT, CSF-1R, Src, c-Kit

Imatinib impurities3

T67847

Synonym:

Target: Bcr-Abl, PDGFR, c-Kit

CHMFL-ABL/KIT-155

T10801

Synonym: CHMFL-ABL-KIT-155

Dasatinib hydrochloride

T22303

Synonym: BMS-354825 HCl

Target: Bcr-Abl, Src, c-Kit

Dasatinib monohydrate

T1448L

Synonym: BMS-354825 Monohydrate

Target: Apoptosis, Bcr-Abl, Src, c-Kit, Ephrin Receptor, Autophagy

Abl Substrate Peptide TFA

Synonym: CGP-57148B D8,STI571 D8

Target: Others

Imatinib D4

T11639

Synonym: CGP-57148B D4,STI571 D4

Target: Bcr-Abl, Src, c-Kit

AEE788

T2116

Synonym: NVP-AEE 788

Target: Apoptosis, EGFR, c-Fms, FLT, Bcr-Abl

N-Desmethyl imatinib mesylate

T40504

Synonym: ImatinibmetaboliteN-Desmethylimatinibmesylate,N-Desmethyl imatinib mesylate,Norimatinib mesylate

Target:

Imatinib hydrochloride

Target: Raf, VEGFR, Bcr-Abl

Target: Apoptosis, Bcr-Abl, Src, c-Kit, Autophagy

Masitinib

T2609

Synonym: AB1010

Target: Apoptosis, FAK, c-Fms, FGFR, Bcr-Abl, PDGFR, Src, c-Kit, Hck

Agerafenib

T2070

Synonym: RXDX-105,CEP 32496,CEP-32496,CEP32496

Target: Raf, c-RET, Bcr-Abl, PDGFR, Src, c-Kit

Ponatinib

T2372

Synonym: AP24534

Target: VEGFR, FGFR, Bcr-Abl, PDGFR, Src, c-Kit, Autophagy

Target: Apoptosis, MEK

Agerafenib hydrochloride

T14928

Synonym: RXDX-105 hydrochloride,CEP-32496 (hydrochloride)

Target: c-RET, c-Kit

Recombinant Proteins

Species：

Expression System：

Tag：

カタログ番号	製品名	Species	Expression System
TMPY-04396	C-ABL/ABL1 Protein, Human, Recombinant (GST)	Human	Baculovirus-Insect Cells
	c-Abl belongs to the class of tyrosine kinases and is the prototype of a subfamily which includes two members, c-Abl and Arg (Abl-related gene). Both proteins are localized at the cell membrane, actin cytoskeleton and cy...
TMPY-03486	PTPN12 Protein, Human, Recombinant (aa 1-355, His & GST)	Human	Baculovirus-Insect Cells
	PTPN12 is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncog...
TMPY-03548	PTPN12 Protein, Human, Recombinant	Human	Baculovirus-Insect Cells
	PTPN12 is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncog...
TMPK-01456	HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)	Human	HEK293
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-pr...
TMPK-01450	HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated	Human	HEK293
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-pr...
TMPK-01451	HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)	Human	HEK293
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-pr...